VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients with histologically confirmed diagnosis   │ Patients with histologically confirmed diagnosis   │     100 │
│ of prostate cancer who have not yet developed bone │ of prostate cancer who have not yet developed bone │         │
│ metastases                                         │ metastases                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prostate cancer patients with a rise in PSA under  │ Prostate cancer patients with a rise in PSA under  │     100 │
│ hormone therapy                                    │ hormone therapy                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ PSA criteria                                       │ PSA criteria                                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have undergone prostatectomy: any     │ Patients who have undergone prostatectomy: any     │     100 │
│ rise in PSA or                                     │ rise in PSA or                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients without prostatectomy: 2 consecutive      │ Patients without prostatectomy: 2 consecutive      │     100 │
│ rises in PSA levels relative to a previous         │ rises in PSA levels relative to a previous         │         │
│ reference value, separated by one month. The first │ reference value, separated by one month. The first │         │
│ measurement must occur one month after the         │ measurement must occur one month after the         │         │
│ reference value and must be above the reference    │ reference value and must be above the reference    │         │
│ value. The second confirmatory measurement taken   │ value. The second confirmatory measurement taken   │         │
│ one month after the first measurement must be      │ one month after the first measurement must be      │         │
│ greater than the first measurement                 │ greater than the first measurement                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous chemotherapy or radiotherapy must have    │ Previous chemotherapy or radiotherapy must have    │     100 │
│ been performed ≥ 8 weeks prior to study entry      │ been performed ≥ 8 weeks prior to study entry      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Eastern Cooperative Oncology Group (ECOG) score of │ Eastern Cooperative Oncology Group (ECOG) score of │     100 │
│ 0, 1 or 2 (patients that spend less than 50% of    │ 0, 1 or 2 (patients that spend less than 50% of    │         │
│ time in bed during the day)                        │ time in bed during the day)                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adequate liver function - serum total bilirubin    │ Adequate liver function - serum total bilirubin    │     100 │
│ concentration less than 1.5 x upper limit of       │ concentration less than 1.5 x upper limit of       │         │
│ normal value                                       │ normal value                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age: ≥ 18 years                                    │ Age: ≥ 18 years                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient has given written informed consent prior   │ Patient has given written informed consent prior   │     100 │
│ to any study-specific procedures. Patients with    │ to any study-specific procedures. Patients with    │         │
│ psychiatric or addictive disorders which prevent   │ psychiatric or addictive disorders which prevent   │         │
│ them from giving their informed consent must not   │ them from giving their informed consent must not   │         │
│ enter the study                                    │ enter the study                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment with a bisphosphonate              │ Prior treatment with a bisphosphonate              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Corrected (adjusted for serum albumin) serum       │ Corrected (adjusted for serum albumin) serum       │     100 │
│ calcium concentration \< 8.0 mg/dl (2.00 mmol/L)   │ calcium concentration < 8.0 mg/dl (2.00 mmol/L) or │         │
│ or ≥ 12.0 mg/dl (3.00 mmol/L)                      │ ≥ 12.0 mg/dl (3.00 mmol/L)                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with clinically symptomatic brain         │ Patients with clinically symptomatic brain         │     100 │
│ metastases                                         │ metastases                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of diseases with influence on bone         │ History of diseases with influence on bone         │     100 │
│ metabolism such as Paget's disease and primary     │ metabolism such as Paget's disease and primary     │         │
│ hyperparathyroidism                                │ hyperparathyroidism                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe physical or psychological concomitant       │ Severe physical or psychological concomitant       │     100 │
│ diseases that might impair compliance with the     │ diseases that might impair compliance with the     │         │
│ provisions of the study protocol or that might     │ provisions of the study protocol or that might     │         │
│ impair the assessment of drug or patient safety,   │ impair the assessment of drug or patient safety,   │         │
│ e.g. clinically significant ascites, cardiac       │ e.g. clinically significant ascites, cardiac       │         │
│ failure, NYHA III or IV, clinically relevant       │ failure, NYHA III or IV, clinically relevant       │         │
│ pathologic findings in ECG                         │ pathologic findings in ECG                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to zoledronic acid or other │ Known hypersensitivity to zoledronic acid or other │     100 │
│ bisphosphonates                                    │ bisphosphonates                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of other investigational drugs 30 days prior   │ Use of other investigational drugs 30 days prior   │     100 │
│ to the date of randomization                       │ to the date of randomization                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known history or present abuse of alcohol or drugs │ Known history or present abuse of alcohol or drugs │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who, in the opinion of the investigator,  │ Subjects who, in the opinion of the investigator,  │     100 │
│ are unlikely to cooperate fully during the study   │ are unlikely to cooperate fully during the study   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current active dental problems including infection │ Current active dental problems including infection │     100 │
│ of the teeth or jawbone (maxilla or mandibular);   │ of the teeth or jawbone (maxilla or mandibular);   │         │
│ dental or fixture trauma, or a current or prior    │ dental or fixture trauma, or a current or prior    │         │
│ diagnosis of osteonecrosis of the jaw (ONJ), of    │ diagnosis of osteonecrosis of the jaw (ONJ), of    │         │
│ exposed bone in the mouth, or of slow healing      │ exposed bone in the mouth, or of slow healing      │         │
│ after dental procedures                            │ after dental procedures                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recent (within 6 weeks) or planned dental or jaw   │ Recent (within 6 weeks) or planned dental or jaw   │     100 │
│ surgery (e.g. extraction, implants)                │ surgery (e.g. extraction, implants)                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other protocol defined inclusion/exclusion         │ Other protocol defined inclusion/exclusion         │     100 │
│ criteria may apply                                 │ criteria may apply                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Abnormal renal function as evidenced by a          │ Abnormal renal function as evidenced by a          │      99 │
│ calculated creatinine clearance \< 30 ml/minute    │ calculated creatinine clearance < 30 ml/minute     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                  │   Score │
╞═══════════════════════════════════╪════════════════════════════════════════════════╪═════════╡
│ Must be MALE                      │ Patients who have undergone prostatectomy: any │      19 │
│                                   │ rise in PSA or                                 │         │
├───────────────────────────────────┼────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years │ Age: ≥ 18 years                                │      46 │
╘═══════════════════════════════════╧════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 94.56
OverAll Ratio: 96.78
